Key Highlights

  • Vivos Therapeutics (NASDAQ:VVOS) reported third-quarter Revenue of USD 6.4 million, down 5% from USD 6.8 million, as product revenue fell USD 423 thousand.
  • Net loss narrowed to USD 1,971 thousand from USD 5,400 thousand, helped by a USD 2.9 million Reversal of an Employee Retention Credit liability.
  • Gross Margin slipped to 52% from 58%, while general and administrative expenses dropped 18% to about USD 6.5 million.
  • Cash was about USD 0.2 million at September 30, 2026, and management says it will not fund operations for the next twelve months.

Service Growth Offsets Weaker Appliance Sales Only in Part

Vivos Therapeutics (NASDAQ:VVOS) is a medical technology and healthcare services company that treats mild to severe obstructive sleep apnea and dentofacial abnormalities with oral appliances and proprietary protocols, and has treated nearly 75,000 patients. It acquired sleep testing and treatment centers from SCN in June 2025, shifting toward a provider-focused model. Its quarterly report, filed November 16, 2026, shows total revenue of USD 6,414 thousand for the quarter ended September 30, 2026, against USD 6,783 thousand.

Product revenue fell to USD 1,772 thousand from USD 2,195 thousand, mainly on about USD 1.1 million fewer appliance sales to VIP members after a change in strategy, partly offset by about USD 0.5 million lower discounts. Service revenue edged up to USD 4,642 thousand, with about USD 1.5 million from sleep testing at SCN and about USD 0.6 million from treatment at two SCN locations.

Retention Credit Reversal Cuts the Loss Despite a Thinner Margin

Cost of sales rose 9% to about USD 3.1 million on higher diagnostic and patient therapy costs, including added staff at treatment centers. Gross Profit fell to USD 3,314 thousand, and gross margin eased to 52% from 58%. General and administrative spending dropped USD 1.4 million, or 18%, to USD 6,450 thousand as professional fees fell USD 0.8 million and prior-year integration costs did not recur.

Operating loss improved to USD 3,896 thousand from USD 4,734 thousand. Other income of USD 2,906 thousand, up from USD 13 thousand, came mostly from reversing about USD 2.9 million of an Employee Retention Credit Liability after management concluded repayment was no longer probable. Other expense rose USD 302 thousand to USD 981 thousand on interest from short-term financing. For nine months, revenue rose 23% to USD 16.7 million but net loss widened to USD 15,245 thousand from USD 14,276 thousand.

Debt-for-Equity Swaps and a Going Concern Warning

Net cash used in Operating Activities was about USD 12.3 million over nine months, compared with USD 11.5 million a year earlier. Accumulated Deficit stood at about USD 140.5 million, and total liabilities at about USD 20.7 million. The company exchanged about USD 6.1 million of senior secured Debt with Streeterville Capital for Equity during 2026, including USD 2,861,270 of principal for 11,445,080 shares on September 2, and closed a USD 2.1 million private Placement on June 30. About USD 2.3 million of principal remains due June 10, 2027.

Management says it has eliminated over USD 5 million in annual operating costs and plans clinical and payer initiatives, such as EEG testing, CPAP distribution and remote monitoring, to lift revenue from the fourth quarter. Shares outstanding were 33,820,768 on November 12, 2026.

Where Things Stand

The headline loss looks better than the Business underneath. Vivos Therapeutics (NASDAQ:VVOS) trimmed its net loss to USD 2.0 million mainly through a one-time credit reversal, while quarterly revenue slipped 5% and cash of USD 0.2 million raises going concern doubt. Watch for fourth-quarter revenue from new clinical programs, the renegotiation of payer contracts, further debt exchanges and equity raises, and the repayment of the remaining USD 2.3 million Streeterville note due in June 2027.